CAR-T cell therapy is emerging as a promising option for people with relapsed or refractory blood cancers, offering a more targeted approach when standard treatments have not worked or the disease has returned. In Ahmedabad, hospitals are nearing 50 CAR-T procedures over the past two years, pointing to growing use of the therapy in clinical care.
The treatment is being seen as a new source of hope for patients and families facing difficult blood cancer cases. Its rise in Ahmedabad also reflects how advanced cancer therapies are gradually becoming available beyond a few select centres, giving more patients access to specialised treatment options.
At the same time, the high cost of CAR-T therapy remains a major barrier. While the procedure can expand choices for blood cancer care, affordability continues to shape who can benefit from it, keeping the discussion around access and cost at the centre of its wider adoption.
Even so, the increase in procedures highlights a shift in how relapsed and refractory blood cancers are being treated. As hospitals build experience with CAR-T therapy, it is increasingly being viewed as an important part of the evolving treatment landscape for blood cancer patients.
